Gracell Biotechnologies to Present at the 20th Annual Needham Virtual Healthcare Conference

SUZHOU, China and SHANGHAI, China, April 05, 2021 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it will present at the 20^th Annual Needham Virtual Healthcare Conference (details below).

Corporate Presentation: 8:45 – 9:25 am ET, Monday, April 12, 2021
Presenter: Dr. William (Wei) Cao, Founder and CEO
Webcast: https://wsw.com/webcast/needham107/grcl/2238544
The webcast and replay of the presentation can also be accessed through the “News and Events” section of the Gracell Investor website.

One-on-one meetings: April 12-15, 2021
Management participants: Dr. William (Wei) Cao, Founder and CEO; Dr. Kevin Xie, CFO

For more information, please contact your Needham representative.

About Gracell

Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.

Media Contact
Marvin Tang
marvin.tang@gracellbio.com

Investor Contact
Gracie Tong
Gracie.tong@gracellbio.com